Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Society of Hematology
2018
|
| _version_ | 1797099716961370112 |
|---|---|
| author | Schuurhuis, G Heuser, M Freeman, S Béné, M Buccisano, F Cloos, J Grimwade, D Haferlach, T Hills, R Hourigan, C Jorgensen, J Kern, W Lacombe, F Maurillo, L Preudhomme, C Van Der Reijden, B Thiede, C Venditti, A Vyas, P Wood, B Walter, R Döhner, K Roboz, G Ossenkoppele, G |
| author_facet | Schuurhuis, G Heuser, M Freeman, S Béné, M Buccisano, F Cloos, J Grimwade, D Haferlach, T Hills, R Hourigan, C Jorgensen, J Kern, W Lacombe, F Maurillo, L Preudhomme, C Van Der Reijden, B Thiede, C Venditti, A Vyas, P Wood, B Walter, R Döhner, K Roboz, G Ossenkoppele, G |
| author_sort | Schuurhuis, G |
| collection | OXFORD |
| description | Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and molecular data assessed at diagnosis. MRD can be evaluated using a variety of multiparameter flow cytometry and molecular protocols, but, to date, these approaches have not been qualitatively or quantitatively standardized, making their use in clinical practice challenging. The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use of MRD in clinical practice. The work was accomplished over 2 years, during 4 meetings by a specially designated MRD Working Party of the European LeukemiaNet. The group included 24 faculty with expertise in AML hematopathology, molecular diagnostics, clinical trials, and clinical medicine, from 19 institutions in Europe and the United States. |
| first_indexed | 2024-03-07T05:27:34Z |
| format | Journal article |
| id | oxford-uuid:e11825d8-0884-496c-b2ca-f8c69c21c9d3 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:27:34Z |
| publishDate | 2018 |
| publisher | American Society of Hematology |
| record_format | dspace |
| spelling | oxford-uuid:e11825d8-0884-496c-b2ca-f8c69c21c9d32022-03-27T09:51:59ZMinimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working PartyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:e11825d8-0884-496c-b2ca-f8c69c21c9d3EnglishSymplectic Elements at OxfordAmerican Society of Hematology2018Schuurhuis, GHeuser, MFreeman, SBéné, MBuccisano, FCloos, JGrimwade, DHaferlach, THills, RHourigan, CJorgensen, JKern, WLacombe, FMaurillo, LPreudhomme, CVan Der Reijden, BThiede, CVenditti, AVyas, PWood, BWalter, RDöhner, KRoboz, GOssenkoppele, GMeasurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and molecular data assessed at diagnosis. MRD can be evaluated using a variety of multiparameter flow cytometry and molecular protocols, but, to date, these approaches have not been qualitatively or quantitatively standardized, making their use in clinical practice challenging. The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use of MRD in clinical practice. The work was accomplished over 2 years, during 4 meetings by a specially designated MRD Working Party of the European LeukemiaNet. The group included 24 faculty with expertise in AML hematopathology, molecular diagnostics, clinical trials, and clinical medicine, from 19 institutions in Europe and the United States. |
| spellingShingle | Schuurhuis, G Heuser, M Freeman, S Béné, M Buccisano, F Cloos, J Grimwade, D Haferlach, T Hills, R Hourigan, C Jorgensen, J Kern, W Lacombe, F Maurillo, L Preudhomme, C Van Der Reijden, B Thiede, C Venditti, A Vyas, P Wood, B Walter, R Döhner, K Roboz, G Ossenkoppele, G Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party |
| title | Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party |
| title_full | Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party |
| title_fullStr | Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party |
| title_full_unstemmed | Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party |
| title_short | Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party |
| title_sort | minimal measurable residual disease in aml a consensus document from the european leukemianet mrd working party |
| work_keys_str_mv | AT schuurhuisg minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT heuserm minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT freemans minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT benem minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT buccisanof minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT cloosj minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT grimwaded minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT haferlacht minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT hillsr minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT houriganc minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT jorgensenj minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT kernw minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT lacombef minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT maurillol minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT preudhommec minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT vanderreijdenb minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT thiedec minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT vendittia minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT vyasp minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT woodb minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT walterr minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT dohnerk minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT robozg minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty AT ossenkoppeleg minimalmeasurableresidualdiseaseinamlaconsensusdocumentfromtheeuropeanleukemianetmrdworkingparty |